廣告
香港股市 已收市
  • 恒指

    16,541.42
    +148.58 (+0.91%)
     
  • 國指

    5,810.79
    +82.66 (+1.44%)
     
  • 上證綜指

    3,041.17
    +30.50 (+1.01%)
     
  • 滬深300

    3,537.48
    +16.52 (+0.47%)
     
  • 美元

    7.8254
    -0.0002 (-0.00%)
     
  • 人民幣

    0.9227
    -0.0001 (-0.01%)
     
  • 道指

    39,807.37
    +47.29 (+0.12%)
     
  • 標普 500

    5,254.35
    +5.86 (+0.11%)
     
  • 納指

    16,379.46
    -20.06 (-0.12%)
     
  • 日圓

    0.0514
    0.0000 (0.00%)
     
  • 歐元

    8.4338
    -0.0068 (-0.08%)
     
  • 英鎊

    9.8760
    0.0000 (0.00%)
     
  • 紐約期油

    83.11
    -0.06 (-0.07%)
     
  • 金價

    2,254.80
    +16.40 (+0.73%)
     
  • Bitcoin

    70,099.77
    -208.41 (-0.30%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

Europe Approves First Bispecific Antibody From Roche For Two Eye Disorders

  • The European Commission approved Roche Holding AG's (OTC: RHHBY) Vabysmo (faricimab) for neovascular or 'wet' age-related macular degeneration (nAMD) and visual impairment due to diabetic macular edema (DME).

  • These retinal conditions affect more than 40 million people globally.

  • Vabysmo is the only injectable eye medicine approved in Europe, with phase 3 studies supporting treatment at intervals of up to four months for people living with nAMD and DME.

  • Also ReadWHO Recommends Against Roche, GSK's COVID-19 Therapies Rendering Them Obsolete

  • The approval is based on four phase 3 studies involving 3,220 patients. The studies showed that people treated with Vabysmo, up to every four months, achieved similar outcomes compared to those receiving treatment every two months with aflibercept.

  • The totality of data across all four studies at two years showed that more than 60% of people treated with Vabysmo could extend treatment to every four months while improving and maintaining vision.

  • Additionally, for up to two years, people with nAMD and DME treated with Vabysmo received 33% (10 vs. 15) and 21% (11 vs. 14) fewer median number of injections than aflibercept, respectively.

  • Vabysmo is now approved in the European Union and nine other countries. Globally, more than 100,000 Vabysmo doses have been distributed.

  • Price Action: RHHBY shares traded lower by 1.70% at $41.63 on the last check Monday.

See more from Benzinga

廣告

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.